drugset / Trial / NCT02914223

A Study to Evaluate Cenerimod in Healthy Male Subjects

NCT02914223

Phase 1 Completed 6 enrolled Viatris Innovation GmbH
Non-randomizedSingle-groupOpen-labelOther

Summary

The main objective of the study is to investigate the rate and routes of elimination of cenerimod and the mass balance in urine, feces, and expired air

Timeline

Start
2016-09-01
Primary completion
2016-12-01
Completion
2016-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cenerimod Small molecule 2 mg Oral

Indications

No indication recorded.